Posted by Michael Wonder on 17 Nov 2015
U.S. Food and Drug Administration accepts for priority review the supplemental biologics license application for Opdivo (nivolumab) in patients with advanced renal cell carcinoma
16 November 2015 - The projected FDA action date is March 16, 2016.
For more details, go to: http://news.bms.com/press-release/us-food-and-drug-administration-accepts-priority-review-supplemental-biologics-license
